Marker Therapeutics Sells Subsidiary
Ticker: MRKR · Form: 8-K · Filed: Dec 17, 2024 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $9.5 Million |
| Sentiment | neutral |
Sentiment: neutral
Topics: divestiture, strategic-shift, subsidiary-sale
TL;DR
Marker Therapeutics selling off its subsidiary to focus on cancer immunotherapies.
AI Summary
Marker Therapeutics, Inc. announced on December 17, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Marker Therapeutics LLC, to a third party. The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions. This sale is part of Marker Therapeutics' strategic plan to focus on its novel cell-based cancer immunotherapies.
Why It Matters
This divestiture signals a strategic shift for Marker Therapeutics, potentially allowing it to concentrate resources on its core immunotherapy pipeline.
Risk Assessment
Risk Level: medium — The sale of a subsidiary can introduce uncertainty regarding future operations and financial stability, while the success of the remaining immunotherapy focus is yet to be proven.
Key Players & Entities
- Marker Therapeutics, Inc. (company) — Registrant
- Marker Therapeutics LLC (company) — Subsidiary being sold
- December 17, 2024 (date) — Date of announcement
- first quarter of 2025 (date) — Expected closing date
FAQ
What is the name of the subsidiary being sold?
The subsidiary being sold is Marker Therapeutics LLC.
When was the definitive agreement for the sale announced?
The definitive agreement was announced on December 17, 2024.
When is the sale of the subsidiary expected to close?
The sale is expected to close in the first quarter of 2025.
What is the strategic reason behind this sale?
The sale is part of Marker Therapeutics' strategic plan to focus on its novel cell-based cancer immunotherapies.
Are there any conditions for the closing of the transaction?
Yes, the transaction is subject to customary closing conditions.
Filing Stats: 450 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-12-17 07:10:42
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar
- $9.5 Million — nouncing that the Company was awarded a $9.5 Million Grant from the Cancer Prevention & Rese
Filing Documents
- tm2431191d1_8k.htm (8-K) — 24KB
- tm2431191d1_ex99-1.htm (EX-99.1) — 16KB
- tm2431191d1_ex99-1img001.jpg (GRAPHIC) — 6KB
- 0001104659-24-129181.txt ( ) — 226KB
- mrkr-20241217.xsd (EX-101.SCH) — 3KB
- mrkr-20241217_lab.xml (EX-101.LAB) — 33KB
- mrkr-20241217_pre.xml (EX-101.PRE) — 22KB
- tm2431191d1_8k_htm.xml (XML) — 4KB
01. Other Information
Item 8.01. Other Information On December 17, 2024, Marker Therapeutics, Inc. (the "Company") issued a press release announcing that the Company was awarded a $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support the clinical investigation of MT-601 in patients with pancreatic cancer. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated December 17, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Marker Therapeutics, Inc. Dated: December 17, 2024 By: /s/ Juan Vera Juan Vera President and Chief Executive Officer